

Marwan Fakih

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5532354/publications.pdf>

Version: 2024-02-01

214
papers

14,509
citations

41627

51
h-index

25983

112
g-index

217
all docs

217
docs citations

217
times ranked

18414
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses. <i>Advances in Radiation Oncology</i> , 2022, 7, 100807.	0.6	4
2	Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided <i><i>RAS/BRAF</i></i> Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 104-109.	1.9	6
3	Exploratory biomarker analyses of the single-arm, phase 2 study of regorafenib plus nivolumab in patients (pts) with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 89-89.	0.8	1
4	Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 446-454.	3.7	36
5	Safety and efficacy of pressurized intraperitoneal aerosolized chemotherapy in appendiceal and colorectal cancer patients with peritoneal carcinomatosis: A first-in-US phase I study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 125-125.	0.8	0
6	Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS669-TPS669.	0.8	0
7	A single-center comparative surveillance strategies of ctDNA (Signatera), imaging, and CEA in the surveillance of resected colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 200-200.	0.8	2
8	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		45
9	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i><i>NTRK</i></i> Fusion-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1302-1312.	3.2	74
10	Real-World Study of Characteristics and Treatment Outcomes Among Patients with <i><i>KRAS</i></i> p.G12C-Mutated or Other <i><i>KRAS</i></i> Mutated Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 663-674.	1.9	21
11	Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e221093.	2.8	21
12	Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAF Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series. <i>Clinical Colorectal Cancer</i> , 2022, 21, 267-271.	1.0	5
13	Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. <i>Science Advances</i> , 2022, 8, eabl9171.	4.7	30
14	A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2022, 21, 252-258.	1.0	3
15	Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design. <i>Pleura and Peritoneum</i> , 2022, 7, 169-177.	0.5	2
16	Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4173-TPS4173.	0.8	0
17	Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer. <i>Communications Medicine</i> , 2022, 2, .	1.9	5
18	Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. <i>European Journal of Cancer</i> , 2022, 171, 259-268.	1.3	19

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 171-181.	1.3	14
20	Wild-type <i>APC</i> Is Associated with Poor Survival in Metastatic Microsatellite Stable Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 208-214.	1.9	19
21	Chemotherapy-induced early transient increase and surge of CA 19â€9 level in patients with pancreatic Adenocarcinomaâ€. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100397.	0.7	1
22	Rationale and Design of a Telehealth Self-Management, Shared Care Intervention for Post-treatment Survivors of Lung and Colorectal Cancer. <i>Journal of Cancer Education</i> , 2021, 36, 414-420.	0.6	6
23	<i>RAS</i> Amplification as a Negative Predictor of Benefit from Anti-EGFRâ€Containing Therapy Regimens in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 469-475.	1.9	7
24	Targeting KRAS in Colorectal Cancer. <i>Current Oncology Reports</i> , 2021, 23, 28.	1.8	24
25	Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. <i>Future Science OA</i> , 2021, 7, FSO662.	0.9	1
26	Sequencing Treatments in Hepatocellular Carcinoma: Will Value Frameworks Provide a Solution?. <i>JCO Oncology Practice</i> , 2021, 17, 164-166.	1.4	3
27	MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway. <i>Clinical Colorectal Cancer</i> , 2021, 20, 72-78.	1.0	10
28	Building External Control Arms From Patient-Level Electronic Health Record Data to Replicate the Randomized IMblaze370 Control Arm in Metastatic Colorectal Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 450-458.	1.0	14
29	Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1347-1357.	1.4	14
30	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 779-789.	5.1	234
31	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. <i>Cancers</i> , 2021, 13, 2776.	1.7	9
32	Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. <i>Future Oncology</i> , 2021, 17, 1977-1985.	1.1	24
33	Recall of Genomic Testing Results Among Patients with Cancer. <i>Oncologist</i> , 2021, 26, e2302-e2305.	1.9	8
34	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e003370.		10
35	Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. <i>JAMA Network Open</i> , 2021, 4, e2118416.	2.8	62
36	Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. <i>Annals of Oncology</i> , 2021, 32, 959-967.	0.6	102

#	ARTICLE	IF	CITATIONS
37	Geriatric Assessmentâ€“Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer. <i>JAMA Oncology</i> , 2021, 7, e214158.	3.4	213
38	Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis. <i>JCI Insight</i> , 2021, 6, .	2.3	11
39	Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.. <i>Journal of Clinical Oncology</i> , 2021, 39, 72-72.	0.8	5
40	Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. <i>Science Advances</i> , 2021, 7, eabi7511.	4.7	23
41	Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 670-674.	2.3	4
42	Locally advanced anal small cell carcinoma with durable complete response to chemoradiation followed by consolidation chemotherapy: case report and literature review. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 3148-3154.	0.6	2
43	The Association of Tumor Laterality and Survival After Cytoreduction for Colorectal Carcinomatosis. <i>Journal of Surgical Research</i> , 2020, 248, 20-27.	0.8	11
44	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1â€“2 trials. <i>Lancet Oncology, The</i> , 2020, 21, 271-282.	5.1	1,034
45	A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases. <i>Oncologist</i> , 2020, 25, 382-e776.	1.9	23
46	Management Considerations for the Surgical Treatment of Colorectal Cancer During the Global Covid-19 Pandemic. <i>Annals of Surgery</i> , 2020, 272, e98-e105.	2.1	37
47	A novel mesenchymalâ€“associated transcriptomic signature for riskâ€“stratification and therapeutic response prediction in colorectal cancer. <i>International Journal of Cancer</i> , 2020, 147, 3250-3261.	2.3	6
48	SUMOylation of E2F1 Regulates Expression of EZH2. <i>Cancer Research</i> , 2020, 80, 4212-4223.	0.4	12
49	KRAS^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020, 383, 1207-1217.	13.9	1,049
50	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. <i>Lancet Oncology, The</i> , 2020, 21, 1353-1365.	5.1	1,363
51	Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer. <i>Oncologist</i> , 2020, 25, e1188-e1194.	1.9	61
52	Integrating Academic and Community Practices in the Management of Colorectal Cancer: The City of Hope Model. <i>Journal of Clinical Medicine</i> , 2020, 9, 1687.	1.0	5
53	The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 581.	1.3	1
54	Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study. <i>Cancers</i> , 2020, 12, 657.	1.7	14

#	ARTICLE	IF	CITATIONS
55	Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 235-243.	1.9	36
56	Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report. <i>JCO Precision Oncology</i> , 2020, 4, 307-318.	1.5	10
57	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2124-2130.	3.2	132
58	Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: A randomized controlled trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12010-12010.	0.8	75
59	Efficacy and safety of entrectinib in patients (pts) with <i>NTRK</i> -fusion positive (<i>NTRK</i> -fp) solid tumors: An updated integrated analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3605-3605.	0.8	33
60	A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4000-4000.	0.8	48
61	CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRAS ^{G12C} , in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4018-4018.	0.8	22
62	Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4020-4020.	0.8	22
63	Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3661-TPS3661.	0.8	8
64	Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-1.	0.8	19
65	A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. <i>Oncotarget</i> , 2020, 11, 1334-1343.	0.8	18
66	Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 798-804.	2.3	33
67	Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3504-3504.	0.8	3
68	Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 116-119.	2.3	4
69	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , 2019, 25, 7035-7045.	3.2	152
70	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. <i>Nature</i> , 2019, 575, 217-223.	18.7	1,375
71	Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. <i>Clinical Colorectal Cancer</i> , 2019, 18, 307-309.	1.0	6
72	Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, 1096-1103.	0.6	456

#	ARTICLE	IF	CITATIONS
73	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 849-861.	5.1	368
74	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2019, 20, 518-530.	5.1	362
75	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1460-1469.	0.8	188
76	Systemic treatment for metastatic colorectal cancer in the era of precision medicine. <i>Journal of Surgical Oncology</i> , 2019, 119, 564-582.	0.8	55
77	A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction. <i>Oncologist</i> , 2019, 24, 1137-1145.	1.9	2
78	A case of class 3 MEK1 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 1140-1143.	0.6	7
79	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. <i>Oncologist</i> , 2019, 24, 1340-1347.	1.9	73
80	Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	46
81	Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme. <i>Cell Chemical Biology</i> , 2019, 26, 278-288.e6.	2.5	36
82	A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. <i>Cancer Discovery</i> , 2019, 9, 384-395.	7.7	88
83	Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. <i>Journal of Clinical Investigation</i> , 2019, 129, 4464-4476.	3.9	64
84	Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule <i>KRAS</i> ^{G12C} inhibitor, in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3003-3003.	0.8	145
85	Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for <i>BRAF</i> V600E-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 688-688.	0.8	14
86	Impact of Surgical Resection on Survival Outcomes After Chemoradiotherapy in Anal Adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1203-1210.	2.3	14
87	PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1026-1030.	2.3	12
88	Targeting <i>HER2</i> in colorectal cancer: The landscape of amplification and short variant mutations in <i>ERBB2</i> and <i>ERBB3</i> . <i>Cancer</i> , 2018, 124, 1358-1373.	2.0	151
89	Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in <i>HER2</i> -Amplified Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 474-477.	1.9	11
90	Rationale, development, and design of the Altering Intake , Managing Symptoms (AIMS) dietary intervention for bowel dysfunction in rectal cancer survivors. <i>Contemporary Clinical Trials</i> , 2018, 68, 61-66.	0.8	12

#	ARTICLE	IF	CITATIONS
91	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 610-617.	0.6	192
92	Immune profiling of microsatellite instability-high and polymerase Îµ (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 404-415.	0.6	49
93	Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. <i>Journal of Gastrointestinal Oncology</i> , 2018, 10, 161-165.	0.6	12
94	Value-based genomics. <i>Oncotarget</i> , 2018, 9, 15792-15815.	0.8	46
95	BEACON CRC study safety lead-in (SLI) in patients with <i>BRAF</i> ^{V600E} metastatic colorectal cancer (mCRC): Efficacy and tumor markers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 627-627.	0.8	32
96	Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a <i>POLE</i> Mutation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 142-147.	2.3	182
97	Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention. <i>European Journal of Oncology Nursing</i> , 2017, 29, 125-134.	0.9	39
98	Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-Fluorouracil and capecitabine toxicity. <i>Cancer</i> , 2017, 123, 345-356.	2.0	91
99	Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. <i>Oncotarget</i> , 2017, 8, 42198-42213.	0.8	49
100	A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres® versus SIR-Spheres® alone in chemotherapy-resistant colorectal cancer liver metastases. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 608-613.	0.6	3
101	Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 962-969.	0.6	23
102	Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 1079-1099.	0.6	34
103	Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 314-323.	0.6	5
104	The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 603-607.	0.6	2
105	Biological Therapy in Colorectal Cancer in the Era of Sidedness. <i>Oncology Times</i> , 2017, 39, 1,9-11.	0.1	3
106	Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.. <i>Journal of Clinical Oncology</i> , 2017, 35, 676-676.	0.8	30
107	A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. <i>Oncotarget</i> , 2017, 8, 79750-79760.	0.8	12
108	MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. <i>Anticancer Research</i> , 2017, 37, 2831-2838.	0.5	11

#	ARTICLE	IF	CITATIONS
109	Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma—2 case reports and a brief review. <i>Journal of Gastrointestinal Oncology</i> , 2016, 6, E98-E102.	0.6	46
110	RAS and BRAF in metastatic colorectal cancer management. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 687-704.	0.6	56
111	Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, e1025-e1034.	2.5	83
112	Pilot study of an interdisciplinary supportive care planning intervention in pancreatic cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 3417-3424.	1.0	13
113	Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. <i>Clinical Therapeutics</i> , 2016, 38, 1376-1391.	1.1	11
114	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 1306-1314.	1.9	36
115	Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal. <i>Nature Communications</i> , 2016, 7, 12326.	5.8	78
116	Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy. <i>Acta Oncologica</i> , 2016, 55, 1392-1399.	0.8	43
117	Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. <i>Pancreas</i> , 2016, 45, 286-292.	0.5	12
118	The state of regional therapy in the management of metastatic colorectal cancer to the liver. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 229-245.	1.1	5
119	HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3517-3517.	0.8	59
120	Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastases. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 128.	0.8	13
121	An update on anti-EGF receptor therapy and the move towards targeted therapy and precision medicine. <i>Colorectal Cancer</i> , 2015, 4, 9-11.	0.8	0
122	Biologic Therapies in Colorectal Cancer: Indications and Contraindications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e197-e206.	1.8	7
123	Metastatic Colorectal Cancer: Current State and Future Directions. <i>Journal of Clinical Oncology</i> , 2015, 33, 1809-1824.	0.8	418
124	Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. <i>Journal of Medical Economics</i> , 2015, 18, 619-628.	1.0	9
125	Vitamin D and colorectal cancer: is it time for D3 supplementation in patients with metastatic disease?. <i>Colorectal Cancer</i> , 2015, 4, 59-62.	0.8	1
126	Accuracy of computed tomography in nodal staging of colon cancer patients. <i>World Journal of Gastrointestinal Surgery</i> , 2015, 7, 116.	0.8	18

#	ARTICLE	IF	CITATIONS
127	p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses. <i>Clinical Cancer Research</i> , 2014, 20, 4459-4470.	3.2	32
128	SIR-Spheres [®] radioembolization in the management of metastatic colorectal cancer: a medical oncology perspective. <i>Colorectal Cancer</i> , 2014, 3, 331-343.	0.8	0
129	A Case of Fibrolamellar Cancer With a Palliative Response and Minor Radiographic Regression With Erlotinib and Bevacizumab Combination Therapy. <i>American Journal of Therapeutics</i> , 2014, 21, e207-e210.	0.5	10
130	The emerging role of neoadjuvant chemotherapy for rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 362-73.	0.6	29
131	Serum Vitamin D Metabolites in Colorectal Cancer Patients Receiving Cholecalciferol Supplementation: Correlation with Polymorphisms in the Vitamin D Genes. <i>Hormones and Cancer</i> , 2013, 4, 242-250.	4.9	34
132	Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine. <i>Future Oncology</i> , 2013, 9, 551-560.	1.1	9
133	TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer. <i>Cancer</i> , 2013, 119, 4290-4298.	2.0	53
134	The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 427-438.	1.1	13
135	Targeting angiogenesis beyond first-line bevacizumab progression: ziv-aflibercept or more bevacizumab?. <i>Colorectal Cancer</i> , 2013, 2, 9-12.	0.8	1
136	A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion. <i>Cancer Medicine</i> , 2013, 2, 334-342.	1.3	50
137	Gastric Cancer, Version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 531-546.	2.3	422
138	Metastatic Colon Cancer, Version 3.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 141-152.	2.3	130
139	Localized Colon Cancer, Version 3.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 519-528.	2.3	81
140	TP53 and Let-7a micro-RNA Regulate K-Ras Activity in HCT116 Colorectal Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e70604.	1.1	22
141	Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma. <i>World Journal of Gastrointestinal Surgery</i> , 2013, 5, 178.	0.8	10
142	Targeted therapies in colorectal cancer: the dos, don'ts, and future directions. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 239-44.	0.6	0
143	Intensive Radiographic and Biomarker Surveillance in Stage II and III Colorectal Cancer. <i>Oncology</i> , 2012, 82, 41-47.	0.9	17
144	Anal Carcinoma, Version 2.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 449-454.	2.3	67

#	ARTICLE	IF	CITATIONS
145	Interview: Recent advances in first-line treatment of metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2012, 1, 111-114.	0.8	0
146	Intensive screening for resected stage II and III colorectal cancer. <i>Colorectal Cancer</i> , 2012, 1, 71-81.	0.8	0
147	Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1528-1564.	2.3	138
148	Phase II Study of Irinotecan and Cetuximab Given Every 2 Weeks as Second-Line Therapy for Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2012, 11, 53-59.	1.0	13
149	A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 743-751.	1.1	40
150	Methyl Selenocysteine: Single-Dose Pharmacokinetics in Men. <i>Cancer Prevention Research</i> , 2011, 4, 1938-1944.	0.7	26
151	Serological immune responses to influenza vaccine in patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 111-115.	1.1	16
152	Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients. <i>Prostate</i> , 2011, 71, 368-372.	1.2	50
153	Making sense of anti-EGFR plus oxaliplatin-based therapy in the first-line treatment of metastatic colorectal cancer. <i>Future Oncology</i> , 2011, 7, 223-226.	1.1	0
154	First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases. <i>Anticancer Research</i> , 2011, 31, 975-8.	0.5	43
155	Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. <i>Anticancer Research</i> , 2011, 31, 4637-40.	0.5	26
156	Anal Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 106-120.	2.3	64
157	Quantitative methodology using CT for predicting survival in patients with metastatic colorectal carcinoma: a pilot study. <i>Clinical Imaging</i> , 2010, 34, 196-202.	0.8	2
158	Analysis of Clinical and Dosimetric Factors Associated With Change in Renal Function in Patients With Gastrointestinal Malignancies After Chemoradiation to the Abdomen. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1193-1198.	0.4	14
159	Renal Atrophy Secondary to Chemoradiotherapy of Abdominal Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 539-546.	0.4	16
160	Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4240-4246.	0.8	129
161	A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 3786-3794.	3.2	40
162	KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice. <i>Clinical Colorectal Cancer</i> , 2010, 9, 22-30.	1.0	22

#	ARTICLE	IF	CITATIONS
163	Efficacy of the Monoclonal Antibody EGFR Inhibitors for the Treatment of Metastatic Colorectal Cancer. <i>Current Oncology</i> , 2010, 17, 3-17.	0.9	63
164	KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2010, 1, 90-6.	0.6	8
165	Positron emission tomography as predictor of rectal cancer response during or following neoadjuvant chemoradiation. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 213.	0.8	7
166	Predictive or non-predictive, prognostic or non-prognostic: Dilemmas generated through small retrospective studies. <i>Journal of Gastrointestinal Oncology</i> , 2010, 1, 72-3.	0.6	1
167	A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 3189-3195.	3.2	61
168	Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301. <i>Journal of Clinical Oncology</i> , 2009, 27, 1800-1805.	0.8	195
169	Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2009, 24, 219-224.	1.0	74
170	A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 65, 33-40.	1.1	41
171	Vitamin D deficiency and insufficiency among patients with prostate cancer. <i>BJU International</i> , 2009, 104, 909-914.	1.3	43
172	A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 242-248.	2.0	15
173	Does Celecoxib Have a Role in the Treatment of Patients with Colorectal Cancer?. <i>Clinical Colorectal Cancer</i> , 2009, 8, 11-14.	1.0	11
174	A Case of 5-Fluorouracil-Induced Acute Psychosis. <i>Clinical Colorectal Cancer</i> , 2009, 8, 166-168.	1.0	7
175	Colon Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 778-831.	2.3	409
176	A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 499-508.	1.1	31
177	Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N 1 , N 11 diethylnorspermine. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 517-527.	1.1	29
178	The Role of Targeted Therapy in the Treatment of Advanced Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2008, 9, 357-374.	1.3	5
179	Significance of Signet-Ring Cells in Patients with Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 50-55.	0.7	95
180	Qualitative radiology assessment of tumor response: does it measure up?. <i>Clinical Imaging</i> , 2008, 32, 136-140.	0.8	2

#	ARTICLE	IF	CITATIONS
181	Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1471-1480.	1.1	12
182	Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. <i>Oncology</i> , 2008, 22, 74-6.	0.4	31
183	A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 1216-1223.	3.2	75
184	Anti-EGFR monoclonal antibody-induced hypomagnesaemia. <i>Lancet Oncology, The</i> , 2007, 8, 366-367.	5.1	22
185	Toxicities and Survival Among Octogenarians and Nonagenarians with Colorectal Cancer Treated with Chemotherapy or Concurrent Chemoradiation Therapy. <i>Clinical Colorectal Cancer</i> , 2007, 6, 362-366.	1.0	13
186	Reversible Grade 4 Hyperbilirubinemia in a Patient with UGT1A1 7/7 Genotype Treated with Irinotecan and Cetuximab. <i>Clinical Colorectal Cancer</i> , 2007, 6, 447-449.	1.0	9
187	Increased Frequency of Uridine Diphosphate Glucuronosyltransferase 1A1 7/7 in Patients Experiencing Severe Irinotecan-Induced Toxicities. <i>Clinical Colorectal Cancer</i> , 2007, 6, 583-587.	1.0	7
188	Safety and Efficacy of First-Line Chemotherapy in Unresected Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2007, 6, 710-715.	1.0	8
189	Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent. <i>Biochemical Pharmacology</i> , 2007, 73, 1280-1287.	2.0	25
190	Selenium metabolites in urine of cancer patients receiving l-selenomethionine at high doses. <i>Toxicology and Applied Pharmacology</i> , 2007, 220, 211-215.	1.3	35
191	A Phase II Study of Gemcitabine and Capecitabine in Advanced Cholangiocarcinoma and Carcinoma of the Gallbladder: A Single-Institution Prospective Study. <i>Annals of Surgical Oncology</i> , 2007, 14, 3202-3209.	0.7	68
192	Cetuximab-Induced Hypomagnesemia in Patients with Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2006, 6, 152-156.	1.0	101
193	Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 465-474.	1.1	8
194	Selenium supplementation and colorectal adenomas: An analysis of the nutritional prevention of cancer trial. <i>International Journal of Cancer</i> , 2006, 118, 1777-1781.	2.3	74
195	Bevacizumab-induced Nasal Septum Perforation. <i>Oncologist</i> , 2006, 11, 85-86.	1.9	50
196	Concurrent oxaliplatin, capecitabine, and radiation therapy in the neoadjuvant therapy of rectal adenocarcinoma: can we get the right dose first?. <i>Annals of Oncology</i> , 2006, 17, 1029-1030.	0.6	0
197	Chemotherapy-Induced Carcinoembryonic Antigen Surge in Patients with Metastatic Colorectal Cancer. <i>Oncology</i> , 2006, 70, 49-53.	0.9	29
198	Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 687-703.	0.9	11

#	ARTICLE	IF	CITATIONS
199	Vitamin D compounds: clinical development as cancer therapy and prevention agents. <i>Anticancer Research</i> , 2006, 26, 2551-6.	0.5	59
200	Prevention of colorectal cancer: an emerging role for high-dose vitamin D supplementation?. <i>Oncology</i> , 2006, 20, 1707-10.	0.4	1
201	Postoperative Computed Tomography Scan Surveillance for Patients With Stage II and III Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 30-35.	0.6	9
202	Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 354-360.	1.1	16
203	Phase I and Pharmacokinetic Study of Weekly Docetaxel, Cisplatin, and Daily Capecitabine in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2005, 11, 5942-5949.	3.2	5
204	Selenium Protects Against Toxicity Induced by Anticancer Drugs and Augments Antitumor Activity: A Highly Selective, New, and Novel Approach for the Treatment of Solid Tumors. <i>Clinical Colorectal Cancer</i> , 2005, 5, 132-135.	1.0	48
205	Phase I and Pharmacologic Study of Intermittently Administered 9-Nitrocamptothecin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2004, 10, 5058-5064.	3.2	17
206	First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising?. <i>Annals of Oncology</i> , 2004, 15, 359.	0.6	0
207	A report of high-dose selenium supplementation: response and toxicities. <i>Journal of Trace Elements in Medicine and Biology</i> , 2004, 18, 69-74.	1.5	175
208	Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 487-496.	1.1	20
209	Anti-tumor activity of calcitriol: pre-clinical and clinical studies. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2004, 89-90, 519-526.	1.2	150
210	Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. <i>Urology</i> , 2002, 60, 553-561.	0.5	64
211	Intramedullary spinal cord metastasis (ISCM) in renal cell carcinoma: A series of six cases. <i>Annals of Oncology</i> , 2001, 12, 1173-1177.	0.6	66
212	Unusual Tumors Involving the Head and Neck Region. <i>Journal of Clinical Oncology</i> , 2001, 19, 4173-4174.	0.8	10
213	Inhibition of prostate cancer growth by estramustine and colchicine. <i>Prostate</i> , 1995, 26, 310-315.	1.2	26
214	Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments. <i>OncoTargets and Therapy</i> , 0, Volume 15, 747-756.	1.0	14